UnknownNot Applicable

Three Types of Nucleotide/Nucleoside Analogues Therapy in Patients With Hepatitis b Virus Related Compensated Cirrhosis

China150 participantsStarted 2019-01-01

Plain-language summary

This study is to investigate the clinical efficacy and safety of three types of nucleotide/nucleoside analogues in treatment of hepatitis b virus related compensated cirrhosis.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Positive hepatitis b surface antigen or hepatitis b virus DNA \> 0.5 year;
✓. Age from 18 to 65 years old;
✓. Hepatitis b virus DNA positive;
✓. Cirrhosis or portal hypertension is found through ultrasonography, computed tomography or magnetic resonance imaging;
✓. Do not receive nucleotide/nucleoside analogues treatment in the past half year.

Exclusion criteria

✕. Complications of decompensated cirrhosis: ascites, gastrointestinal bleeding, hepatic encephalopathy, hepatorenal syndrome, etc;
✕. Other active liver diseases;
✕. Hepatocellular carcinoma or other malignancy;
✕. Pregnancy or lactation;
✕. Human immunodeficiency virus infection or congenital immune deficiency diseases;
✕. Severe diabetes, autoimmune diseases;
✕. Other important organ dysfunctions;
✕. Using glucocorticoid;

What they're measuring

Incidence of decompensated cirrhosis

Timeframe: 144 week

Trial details

NCT IDNCT04196998

SponsorThird Affiliated Hospital, Sun Yat-Sen University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-12

Contact for this trial

Wenxiong Xu, Doctor

+8613760783281 xwx1983@163.com

View on ClinicalTrials.gov More Hepatitis B trials